1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Post-Operative Pain - Pipeline Review, H1 2017

Post-Operative Pain - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 187 pages

Post-Operative Pain - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Operative Pain – Pipeline Review, H1 2017, provides an overview of the Post-Operative Pain (Central Nervous System) pipeline landscape.

Pain is one of the main postoperative adverse outcomes causing distress to patients. Degree of postoperative pain experienced by individuals varies. Cause of pain includes peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Operative Pain – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Post-Operative Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Operative Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 9, 16, 10, 13, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively.

Post-Operative Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Post-Operative Pain - Pipeline Review, H1 2017
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Post-Operative Pain - Overview 8
Post-Operative Pain - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Post-Operative Pain - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Post-Operative Pain - Companies Involved in Therapeutics Development 30
AcelRx Pharmaceuticals Inc 30
Adynxx Inc 30
AngioChem Inc 31
Aoxing Pharmaceutical Company Inc 31
AskAt Inc 31
Boehringer Ingelheim GmbH 32
Camurus AB 33
Cara Therapeutics Inc 33
Colby Pharmaceutical Company 34
Cytogel Pharma LLC 34
Dompe Farmaceutici SpA 35
DURECT Corp 35
Eupraxia Pharmaceuticals Inc 36
EyeGate Pharmaceuticals Inc 36
Fujimoto Pharmaceutical Corp 37
Grunenthal GmbH 37
GW Pharmaceuticals Plc 38
Heron Therapeutics Inc 38
Immupharma Plc 39
Innocoll AG 39
INSYS Therapeutics Inc 40
iX Biopharma Ltd 40
Laboratorios Del Dr Esteve SA 41
Lipocure Ltd 41
Liquidia Technologies Inc 42
Medtronic Plc 42
Novartis AG 43
Orbis Biosciences Inc 43
Orion Oyj 44
Pacira Pharmaceuticals Inc 44
PainReform Ltd 45
Pharmazz Inc 45
PhytoHealth Corp 46
PixarBio Corp 46
Proteus SA 47
Recro Pharma Inc 47
Relmada Therapeutics Inc 48
Serina Therapeutics Inc 48
SteadyMed Therapeutics Inc 49
Teikoku Pharma USA Inc 49
The Medicines Company 50
Trevena Inc 50
Post-Operative Pain - Drug Profiles 51
(bupivacaine hydrochloride + meloxicam) ER - Drug Profile 51
(buprenorphine hydrochloride + granisetron hydrochloride) ER - Drug Profile 54
A-100 - Drug Profile 55
ANG-2002 - Drug Profile 56
ARX-04 - Drug Profile 57
AYX-1 - Drug Profile 64
BI-1026706 - Drug Profile 67
bupivacaine hydrochloride - Drug Profile 69
bupivacaine hydrochloride - Drug Profile 70
bupivacaine hydrochloride - Drug Profile 71
bupivacaine hydrochloride - Drug Profile 72
bupivacaine hydrochloride SR - Drug Profile 74
bupivacaine hydrochloride SR - Drug Profile 79
buprenorphine hydrochloride - Drug Profile 80
CAM-2048 - Drug Profile 81
carbamazepine - Drug Profile 82
CPC-111 - Drug Profile 83
CPC-123 - Drug Profile 84
Cyt-1010 - Drug Profile 85
dexamethasone acetate - Drug Profile 87
dexmedetomidine hydrochloride - Drug Profile 92
DF-2755A - Drug Profile 93
difelikefalin - Drug Profile 94
ECP-1014 - Drug Profile 103
fadolmidine hydrochloride - Drug Profile 104
fentanyl - Drug Profile 105
gonyautoxin - Drug Profile 106
grapiprant - Drug Profile 107
HTX-009 - Drug Profile 109
HYLP-002 - Drug Profile 110
IPP-102199 - Drug Profile 111
ketamine hydrochloride - Drug Profile 112
ketorolac tromethamine - Drug Profile 114
lacosamide - Drug Profile 115
levorphanol tartrate ER - Drug Profile 116
MDT-10013 - Drug Profile 118
meloxicam - Drug Profile 119
meloxicam ER - Drug Profile 123
MR-309 - Drug Profile 124
nabiximols - Drug Profile 126
nalbuphine hydrochloride - Drug Profile 133
neosaxitoxin - Drug Profile 134
oliceridine - Drug Profile 136
oxethazaine - Drug Profile 141
PMZ-2010 - Drug Profile 142
RBM-004 - Drug Profile 144
ropivacaine - Drug Profile 145
ropivacaine ER - Drug Profile 146
SAF-312 - Drug Profile 147
SER-226 - Drug Profile 148
Small Molecule for Post-Operative Pain - Drug Profile 149
sufentanil citrate - Drug Profile 150
tapentadol hydrochloride - Drug Profile 158
tilidine hydrochloride - Drug Profile 160
tramadol hydrochloride - Drug Profile 161
tramadol hydrochloride ER - Drug Profile 162
URB-937 - Drug Profile 163
VVZ-149 - Drug Profile 164
Post-Operative Pain - Dormant Projects 165
Post-Operative Pain - Discontinued Products 168
Post-Operative Pain - Product Development Milestones 169
Featured News and Press Releases 169
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 182
Disclaimer 183

List of Tables
Number of Products under Development for Post-Operative Pain, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Post-Operative Pain - Pipeline by AcelRx Pharmaceuticals Inc, H1 2017
Post-Operative Pain - Pipeline by Adynxx Inc, H1 2017
Post-Operative Pain - Pipeline by AngioChem Inc, H1 2017
Post-Operative Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017
Post-Operative Pain - Pipeline by AskAt Inc, H1 2017
Post-Operative Pain - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Post-Operative Pain - Pipeline by Camurus AB, H1 2017
Post-Operative Pain - Pipeline by Cara Therapeutics Inc, H1 2017
Post-Operative Pain - Pipeline by Colby Pharmaceutical Company, H1 2017
Post-Operative Pain - Pipeline by Cytogel Pharma LLC, H1 2017
Post-Operative Pain - Pipeline by Dompe Farmaceutici SpA, H1 2017
Post-Operative Pain - Pipeline by DURECT Corp, H1 2017
Post-Operative Pain - Pipeline by Eupraxia Pharmaceuticals Inc, H1 2017
Post-Operative Pain - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
Post-Operative Pain - Pipeline by Fujimoto Pharmaceutical Corp, H1 2017
Post-Operative Pain - Pipeline by Grunenthal GmbH, H1 2017
Post-Operative Pain - Pipeline by GW Pharmaceuticals Plc, H1 2017
Post-Operative Pain - Pipeline by Heron Therapeutics Inc, H1 2017
Post-Operative Pain - Pipeline by Immupharma Plc, H1 2017
Post-Operative Pain - Pipeline by Innocoll AG, H1 2017
Post-Operative Pain - Pipeline by INSYS Therapeutics Inc, H1 2017
Post-Operative Pain - Pipeline by iX Biopharma Ltd, H1 2017
Post-Operative Pain - Pipeline by Laboratorios Del Dr Esteve SA, H1 2017
Post-Operative Pain - Pipeline by Lipocure Ltd, H1 2017
Post-Operative Pain - Pipeline by Liquidia Technologies Inc, H1 2017
Post-Operative Pain - Pipeline by Medtronic Plc, H1 2017
Post-Operative Pain - Pipeline by Novartis AG, H1 2017
Post-Operative Pain - Pipeline by Orbis Biosciences Inc, H1 2017
Post-Operative Pain - Pipeline by Orion Oyj, H1 2017
Post-Operative Pain - Pipeline by Pacira Pharmaceuticals Inc, H1 2017
Post-Operative Pain - Pipeline by PainReform Ltd, H1 2017
Post-Operative Pain - Pipeline by Pharmazz Inc, H1 2017
Post-Operative Pain - Pipeline by PhytoHealth Corp, H1 2017
Post-Operative Pain - Pipeline by PixarBio Corp, H1 2017
Post-Operative Pain - Pipeline by Proteus SA, H1 2017
Post-Operative Pain - Pipeline by Recro Pharma Inc, H1 2017
Post-Operative Pain - Pipeline by Relmada Therapeutics Inc, H1 2017
Post-Operative Pain - Pipeline by Serina Therapeutics Inc, H1 2017
Post-Operative Pain - Pipeline by SteadyMed Therapeutics Inc, H1 2017
Post-Operative Pain - Pipeline by Teikoku Pharma USA Inc, H1 2017
Post-Operative Pain - Pipeline by The Medicines Company, H1 2017
Post-Operative Pain - Pipeline by Trevena Inc, H1 2017
Post-Operative Pain - Dormant Projects, H1 2017
Post-Operative Pain - Dormant Projects, H1 2017 (Contd..1), H1 2017
Post-Operative Pain - Dormant Projects, H1 2017 (Contd..2), H1 2017
Post-Operative Pain - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Post-Operative Pain, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Dental Pain - Pipeline Review, H2 2016

Dental Pain - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Dental Pain - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dental Pain - Pipeline Review, H2 2016, provides an overview of the ...

Presbyopia - Pipeline Review, H2 2016

Presbyopia - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Presbyopia - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia – Pipeline Review, H2 2016, provides an overview of the ...

Cancer Pain - Pipeline Review, H2 2016

Cancer Pain - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • November 2016
  • by Global Markets Direct

Cancer Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain – Pipeline Review, H2 2016, provides an overview of the ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.